Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: Double-blind, randomized, placebo-controlled trial

Helicobacter

Volumn 12, Issue 5, 2007, Pages 477-485

  De Leest, Helena T J I ^a   Steen, Kirsti S S ^a   Lems, Willem F ^a   Bijlsma, Johannes W J ^b   Van De Laar, Mart A F J ^c   Huisman, A Margriet ^b   Vonkeman, Harald E ^c   Houben, Harry H M L ^d   Kadir, Sylvana W ^e   Kostense, Piet J ^a   Van Tulder, Maurits W ^a   Kuipers, Ernst J ^f   Boers, Maarten ^a   Dijkmans, Ben A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d Zuyderland Medical Centre   (Netherlands)

^e RIJNSTATE HOSPITAL   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti inflammatory agents; Anti ulcer agents; Duodenal ulcer; Helicobacter pylori; Non steroidal; Stomach ulcer

Indexed keywords

AMOXICILLIN; CELECOXIB; CLARITHROMYCIN; DICLOFENAC; IBUPROFEN; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; ROFECOXIB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTRODUODENAL ULCER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STOMACH PROTECTION; TREATMENT OUTCOME;

AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; TIME FACTORS; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 34548186716     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00543.x     Document Type: Article

References (38)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 340 : 1888 99.
2. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000 119 : 521 35.
3. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. The prevention of chronic NSAID-induced upper gastrointestinal toxicity: a Cochrane collaboration meta-analysis of randomized controlled trials. J Rheumatol 2000 27 : 2203 14.
4. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 284 : 1247 55.
5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 343 : 2.
6. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984 1 : 1311 5.
7. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002 359 : 14 22.
8. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996 110 : 1244 52.
9. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995 9 : 59 69.
10. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998 352 : 1016 21.
11. Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003 17 : 799 805.
12. Savary M, Miller G. The Oesophagus: Handbook and Atlas of Endoscopy. Solothurn, Switzerland : Grassman, 1987.
13. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996 20 : 1161 81.
14. Svedlund J, Sjodin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988 33 : 129 34.
15. Bruce B, Fries JF. The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003 1 : 20.
16. EuroQol. A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990 16 : 199 208.
17. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998 51 : 1055 68.
18. Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000 53 : 688 95.
19. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn NSAID-gebruik en preventie van maagschade. Alphen aan den Rijn, The Netherlands : Van Zuiden Communications B.V, 2003 (http://www.cbo.nl).
20. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997 350 : 975 9.
21. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti- inflammatory drugs: a randomised trial. Lancet 2002 359 : 9 13.
22. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002 51 : 329 35.
23. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002 16 : 167 80.
24. Bannwarth B, Dorval E, Caekaert A, Barthelemy P. Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole. J Rheumatol 2002 29 : 1975 80.
25. Lerang F, Moum B, Mowinckel P, et al. Accuracy of seven different tests for the diagnosis of Helicobacter pylori infection and the impact of H2-receptor antagonists on test results. Scand J Gastroenterol 1998 33 : 364 9.
26. Meijer BC, Thijs JC, Kleibeuker JH, van Zwet AA, Berrelkamp RJ. Evaluation of eight enzyme immunoassays for detection of immunoglobulin G against Helicobacter pylori. J Clin Microbiol 1997 35 : 292 4.
27. van de Wouw BA, de Boer WA, Jansz AR, Roymans RT, Staals AP. Comparison of three commercially available enzyme-linked immunosorbent assays and biopsy-dependent diagnosis for detecting Helicobacter pylori infection. J Clin Microbiol 1996 34 : 94 7.
28. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994 47 : 731 7.
29. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000 95 : 1681 90.
30. Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003 52 : 820 6.
31. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999 117 : 776 83.
32. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999 282 : 1921 8.
33. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 81.
34. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998 93 : 2037 46.
35. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002 46 : 328 46.
36. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004 50 : 2433 40.
37. Steen KS, Lems WF, Aertsen J, Bezemer D, Dijkmans BA. Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis. Ann Rheum Dis 2001 60 : 443 7.
38. Graham DY. NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med 2002 347 : 2162 4.